BIOMARKER:

EGFR exon 20 insertion

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

Lung Non-Squamous Non-Small Cell Cancer

Lung Non-Small Cell Squamous Cancer

Solid Tumor

Thymic Carcinoma

furmonertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|furmonertinib

EGFR exon 20 insertion|Lung Non-Squamous Non-Small Cell Cancer|furmonertinib

afatinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|afatinib

EGFR exon 20 insertion|Lung Adenocarcinoma|afatinib

amivantamab-vmjw

EGFR exon 20 insertion|Non Small Cell Lung Cancer|amivantamab-vmjw

EGFR exon 20 insertion|Lung Non-Squamous Non-Small Cell Cancer|amivantamab-vmjw

bevacizumab

EGFR exon 20 insertion|Non Small Cell Lung Cancer|bevacizumab

EGFR exon 20 insertion|Lung Adenocarcinoma|bevacizumab

tarloxotinib bromide

EGFR exon 20 insertion|Non Small Cell Lung Cancer|tarloxotinib bromide

bevacizumab + osimertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|bevacizumab + osimertinib

aumolertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|aumolertinib

PH001

EGFR exon 20 insertion|Non Small Cell Lung Cancer|PH001

ORIC-114

EGFR exon 20 insertion|Non Small Cell Lung Cancer|ORIC-114

cisplatin + pemetrexed

EGFR exon 20 insertion|Non Small Cell Lung Cancer|cisplatin + pemetrexed

camrelizumab + rivoceranib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|camrelizumab + rivoceranib

EGFR inhibitor

EGFR exon 20 insertion|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR exon 20 insertion|Lung Non-Small Cell Squamous Cancer|EGFR inhibitor

PD1 inhibitor

EGFR exon 20 insertion|Non Small Cell Lung Cancer|PD1 inhibitor

Platinum alkylating agent

EGFR exon 20 insertion|Non Small Cell Lung Cancer|Platinum alkylating agent

Immunotherapy

EGFR exon 20 insertion|Non Small Cell Lung Cancer|Immunotherapy

KN046

EGFR exon 20 insertion|Non Small Cell Lung Cancer|KN046

pembrolizumab

EGFR exon 20 insertion|Non Small Cell Lung Cancer|pembrolizumab

anlotinib + sintilimab

EGFR exon 20 insertion|Non Small Cell Lung Cancer|anlotinib + sintilimab

Angiogenesis inhibitor

EGFR exon 20 insertion|Non Small Cell Lung Cancer|Angiogenesis inhibitor

anlotinib + furmonertinib

EGFR exon 20 insertion|Lung Adenocarcinoma|anlotinib + furmonertinib

DZD9008

EGFR exon 20 insertion|Non Small Cell Lung Cancer|DZD9008

CLN-081

EGFR exon 20 insertion|Non Small Cell Lung Cancer|CLN-081

cetuximab + afatinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|cetuximab + afatinib

osimertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|osimertinib

EGFR exon 20 insertion|Lung Adenocarcinoma|osimertinib

BDTX-189

EGFR exon 20 insertion|Solid Tumor|BDTX-189

poziotinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|poziotinib

dacomitinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|dacomitinib

anlotinib

EGFR exon 20 insertion|Thymic Carcinoma|anlotinib

bevacizumab + cetuximab

EGFR exon 20 insertion|Lung Adenocarcinoma|bevacizumab + cetuximab

mobocertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|mobocertinib

bevacizumab + mobocertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|bevacizumab + mobocertinib

BLU-451

EGFR exon 20 insertion|Non Small Cell Lung Cancer|BLU-451

EGFR exon 20 insertion|Solid Tumor|BLU-451

U3-1402

EGFR exon 20 insertion|Non Small Cell Lung Cancer|U3-1402

ABCP

EGFR exon 20 insertion|Non Small Cell Lung Cancer|ABCP

icotinib + furmonertinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|icotinib + furmonertinib

osimertinib + JMT101

EGFR exon 20 insertion|Non Small Cell Lung Cancer|osimertinib + JMT101

durvalumab

EGFR exon 20 insertion|Non Small Cell Lung Cancer|durvalumab

gefitinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|gefitinib

TAS2940

EGFR exon 20 insertion|Solid Tumor|TAS2940

TY-4028

EGFR exon 20 insertion|Non Small Cell Lung Cancer|TY-4028

osimertinib + AZD9592

EGFR exon 20 insertion|Non Small Cell Lung Cancer|osimertinib + AZD9592

GB263T

EGFR exon 20 insertion|Non Small Cell Lung Cancer|GB263T

erlotinib

EGFR exon 20 insertion|Non Small Cell Lung Cancer|erlotinib